IL17A and myeloid sarcoma: Neurofilament light (NF-L), glial fibrillary acidic protein (GFAP), and cytokines (IL-17, IL-6, IL-10, TNF-α, IFN-γ, and IL-12) are emerging biomarkers for determining inflammatory disease activity, disease progression, treatment response, and prognosis in MS patients [17,18,19,20,21].